IP Library Granted Patent US 10,829,499
Granted Patent B2
US 10,829,499 · App. 16/447,271 · Granted Nov 10, 2020

Tetracyclic heterocycle compounds useful as HIV integrase inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,499
App. No.
16/447,271
Granted
Nov 10, 2020
Kind
B2
Abstract

The present invention relates to Tetracyclic Heterocycle Compounds of Formula and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R 1 , R 2 , R 3 and R 7 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Claims (28)

1. A pharmaceutical composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof, doravirine and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 comprising:

or a pharmaceutically acceptable salt thereof, doravirine and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 1 comprising:

or a pharmaceutically acceptable salt thereof, doravirine and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 1 comprising:

or a pharmaceutically acceptable salt thereof, doravirine and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 1 comprising:

or a pharmaceutically acceptable salt thereof, doravirine and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 1 comprising:

or a pharmaceutically acceptable salt thereof, doravirine and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 1 comprising:

or a pharmaceutically acceptable salt thereof, doravirine and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof, 4′-ethynyl-2-fluoro-2′-deoxyadenosine and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8 comprising:

or a pharmaceutically acceptable salt thereof, 4′-ethynyl-2-fluoro-2′-deoxyadenosine and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 8 comprising:

or a pharmaceutically acceptable salt thereof, 4′-ethynyl-2-fluoro-2′-deoxyadenosine and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 8 comprising:

or a pharmaceutically acceptable salt thereof, 4′-ethynyl-2-fluoro-2′-deoxyadenosine and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 8 comprising:

or a pharmaceutically acceptable salt thereof, 4′-ethynyl-2-fluoro-2′-deoxyadenosine and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 8 comprising:

or a pharmaceutically acceptable salt thereof, 4′-ethynyl-2-fluoro-2′-deoxyadenosine and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 8 comprising:

or a pharmaceutically acceptable salt thereof, 4′-ethynyl-2-fluoro-2′-deoxyadenosine and a pharmaceutically acceptable carrier.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2019
From: GRAHAM, THOMAS H.; YU, TAO; ZHANG, YONGLIAN; MCCAULEY, JOHN A.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 049539/0732 →